USANA Health Sciences, Inc. (NYSE:USNA) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus estimate of $4.06. The company issued revenue guidance of $1.02-1.03 billion, compared to the consensus revenue estimate of $1.07 billion.
USANA Health Sciences, Inc. (USNA) traded up 1.29% on Friday, hitting $58.80. 120,279 shares of the stock traded hands. The stock has a 50-day moving average price of $61.41 and a 200 day moving average price of $60.57. USANA Health Sciences, Inc. has a 12-month low of $52.55 and a 12-month high of $150.00. The stock has a market cap of $1.44 billion, a P/E ratio of 15.27 and a beta of 1.10.
USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, July 25th. The company reported $0.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by $0.08. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The firm had revenue of $257.10 million for the quarter, compared to the consensus estimate of $273.61 million. During the same quarter in the previous year, the business posted $2.07 EPS. The firm’s revenue for the quarter was down .5% compared to the same quarter last year. On average, equities analysts expect that USANA Health Sciences, Inc. will post $3.79 EPS for the current fiscal year.
USANA Health Sciences announced that its Board of Directors has approved a stock repurchase program on Tuesday, July 25th that authorizes the company to buyback $64.60 million in shares. This buyback authorization authorizes the company to buy up to 46% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.
Several analysts have recently commented on the stock. BidaskClub downgraded shares of USANA Health Sciences from a sell rating to a strong sell rating in a research report on Monday, July 31st. Pivotal Research reduced their price objective on shares of USANA Health Sciences from $75.00 to $70.00 and set a buy rating for the company in a research report on Wednesday, July 26th.
In related news, insider Paul A. Jones sold 9,851 shares of USANA Health Sciences stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $64.50, for a total value of $635,389.50. Following the completion of the sale, the insider now owns 6,020 shares of the company’s stock, valued at approximately $388,290. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gilbert A. Fuller sold 1,483 shares of USANA Health Sciences stock in a transaction on Monday, July 31st. The shares were sold at an average price of $57.67, for a total transaction of $85,524.61. Following the completion of the sale, the director now directly owns 1,483 shares of the company’s stock, valued at approximately $85,524.61. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 171,334 shares of company stock valued at $10,413,675. Insiders own 53.20% of the company’s stock.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.